Editor's Pick

Jun 15, 2022

Estimated Total Tumor mRNA Predicts Cancer Outcomes, Study Shows
Premium

Jun 8, 2022

New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur
Premium

May 20, 2022

MSK Starts Offering Pediatric Cancer Patients Whole-Genome, Transcriptome Sequencing
Premium

May 20, 2022

Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests

Apr 8, 2022

Tempus Sets Sights on Pathology Market With New Informatics, Research Network
Premium

Jan 19, 2022

Protein-Based Liquid Biopsy Panel Assesses Tumor Microenvironment, Shows Prognostic Potential
Premium

Jan 7, 2022

Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom
Premium

Dec 9, 2021

RxPONDER Update Yields No Clear Guidance on Chemo Decisions for Younger Breast Cancer Patients
Premium

Nov 11, 2021

Sysmex Inostics Sees Ultra-Sensitive Leukemia Liquid Biopsy as Potential CDx
Premium

Nov 9, 2021

Invitae Unveils Plans to Expand Cancer Testing Portfolio
Premium

Oct 28, 2021

BGI Genomics Program Seeks to Validate Signatera Test for Colorectal Cancer Patients in China
Premium

Oct 25, 2021

Labs Ask Medicare Contractor to Refine Coverage Policy for 'Comprehensive' NGS Cancer Testing
Premium

Oct 11, 2021

EU IVDR Implementation Woes Could Severely Limit Cancer Companion Test, Precision Therapy Access
Premium

Sep 10, 2021

Strata Oncology Trial Data Support Robustness of NGS Assay for Challenging Samples
Premium

Aug 18, 2021

Datar Cancer Genetics Expands Business from Treatment Monitoring to Dx and Screening
Premium

Aug 5, 2021

NYU Langone Health, Philips Integrate Informatics for FDA-Cleared Cancer Sequencing Panel
Premium

Aug 5, 2021

State-Regulated Illinois Health Plans Subject to Biomarker Test Coverage Mandate Starting 2022
Premium

Jul 22, 2021

Natera Minimal Residual Disease Test Predicts Oligometastatic CRC Patient Outcomes in New Study
Premium

Jun 22, 2021

Guardant Health Targets Emerging Treatment Response Market With New ctDNA Product
Premium

Jun 18, 2021

Natera Aims to Lead Market in Solid Tumor Adjuvant CDx, Supported by New Liquid Biopsy Data
Premium